Three years of experience with bisoprolol in the treatment of mild to moderate hypertension.
Long-term efficacy and safety of the beta1-selective adrenoceptor-blocking agent bisoprolol was investigated in 164 patients with mild to moderate essential hypertension who had already been treated successfully with bisoprolol once daily for 1 year in preceding studies. The good therapeutic effect of bisoprolol was maintained for another 1 or 2 years. There was no need for further dose adaptations, and the patients remained on their individually titrated dose. At the end of the third year, 22.6% of the patients required 5 mg or less, 63.7% needed 10 mg, and 13.7% of the patients required 20 mg. Four patients received a diuretic in addition to maintain a reasonable blood pressure reduction. Thirty-four of the 164 patients experienced adverse events, which necessitated a premature study withdrawal only in 2 cases. The repeatedly checked laboratory parameters did not adversely change under long-term treatment with bisoprolol up to 36 months. In particular, this also holds true for total cholesterol, triglycerides, and blood glucose.
Giesecke
H G
HG
Clinical Research Department, E. Merck, Darmstadt, FRG.
Buchner-Möll
D
D
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D017298:Bisoprolol / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D017298:Bisoprolol